Personalis, Inc. (PSNL)
| Market Cap | 1.65B |
| Revenue (ttm) | 76.63M |
| Net Income (ttm) | -34.58M |
| Shares Out | 35.46M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $42.47 |
| Previous Close | $46.91 |
| Change ($) | -4.44 |
| Change (%) | -9.46% |
| Day's Open | 46.24 |
| Day's Range | 42.02 - 48.01 |
| Day's Volume | 846,862 |
| 52-Week Range | 4.75 - 51.02 |
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announce...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten ...
A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the f...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- #AACR20--Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program
MENLO PARK, Calif.--(BUSINESS WIRE)-- #EACR--Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event
Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.
MENLO PARK, Calif.--(BUSINESS WIRE)-- #AMP2020--Personalis® to Present at the AMP Annual Meeting 2020
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
Personalis' (PSNL) CEO John West on Q3 2020 Results - Earnings Call Transcript
Personalis (PSNL) delivered earnings and revenue surprises of 10.00% and 2.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter...
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcomi...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis to Participate in Immuno Series US Virtual Meeting
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc. to Present at IO Combinations 360˚
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis to Participate in Digital World CB & CDx Meeting
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Receives Contract Extension and New Task Order from the VA’s Million Veteran Program – Total Awarded to Date Now $175M
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Strengthens Commercial Team with the Appointment of New Head of Population Genomics
Personalis (PSNL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
The company, which leans on one customer for 76% of revenue, desperately needs to diversify its customer base.
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference
The genomics company announced a public offering of common stock.
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Pricing of Public Offering of Common Stock
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Launch of Public Offering of Common Stock
Personalis, Inc. (PSNL) CEO John West on Q2 2020 Results - Earnings Call Transcript
Personalis (PSNL) delivered earnings and revenue surprises of 14.71% and 14.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis Reports Second Quarter 2020 Financial Results
Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platform
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc.
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Personalis: Buy This Disruptor In Precision Medicine And Machine Learning
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Announce Second Quarter 2020 Financial Results on August 6, 2020
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Expands Leadership Team with Appointment of Leslie Grab, VP of Intellectual Property & John Lyle, VP of Assay Research and ...
As of late, it has definitely been a great time to be an investor in Personalis, Inc. (PSNL).
NEW YORK, June 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Personalis, Inc. ("Personalis" or the "Company") (NASDAQ: PSNL). Such investors are advi...
NEW YORK, June 2, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Personalis, Inc. ("Personalis" or...
Personalis, Inc. (PSNL) CEO John West on Q1 2020 Results - Earnings Call Transcript
Personalis, Inc. (PSNL) CEO John West on Q4 2019 Results - Earnings Call Transcript
These small-cap biopharma stocks offer intriguing potential in 2020 and beyond.
Personalis: A Speculative Position Seems Warranted Here
Personalis, Inc. (PSNL) CEO John West on Q3 2019 Results - Earnings Call Transcript
MIrati Therapeutics, Iovance Biotherapeutics, and Personalis are all using genetic knowledge to help find cures for cancer.
Is Wall Street's initial excitement giving way to more realistic expectations?
About PSNL
Personalis operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. Personalis, Inc. has part... [Read more...]
| Industry Diagnostics & Research | IPO Date Jun 20, 2019 |
| CEO John West | Employees 181 |
| Stock Exchange NASDAQ | Ticker Symbol PSNL |
Financial Performance
In 2019, Personalis's revenue was $65.21 million, an increase of 72.62% compared to the previous year's $37.77 million. Losses were -$25.08 million, 26.1% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for Personalis stock is "Buy." The 12-month stock price forecast is 40.67, which is a decrease of -4.24% from the latest price.